Latest Medicine stories from Life.
Strategic angle: In a new study, bats lap up vaccine-laced saline or chow down on vaccine-carrying mosquitoes. Will that have any impact on the flying mammal's immune system?
Strategic angle: An international team of researchers has achieved a breakthrough in the production of doxorubicin, a vital chemotherapy agent.
Strategic angle: Exploring the ongoing battle over drug pricing and the contrasting approaches of Trump and Biden.
Most Across Political Parties Want Government to Do More to Regulate Prices
Strategic angle: Trump is drawing more attention to his efforts to lower drug prices, like TrumpRx.
Strategic angle: Scientists at the University of Cambridge have developed a new way to alter complex drug molecules using light rather than toxic chemicals.
Strategic angle: Trump emphasizes his commitment to lowering drug prices while criticizing Rep. Massie during campaign stops.
Strategic angle: The federal government negotiates prices for high-cost drugs under Medicare Part B and Part D.
This approval follows previous claims of its potential use in treating autism symptoms.
Strategic angle: In medical school, a student writes, she has learned to react first, focus on prevention later.
Strategic angle: Exploring the advancements in multi-modal large language models for medical applications.
Strategic angle: A team from University of Toronto Engineering pioneers a new approach to drug discovery by synthesizing long noncoding RNA outside the cell.
Strategic angle: Sen. Ron Johnson raises concerns about the FDA's handling of treatments for rare diseases after discussions with Commissioner Marty Makary.
Strategic angle: A coalition of Kennedy's allies gathered to discuss vaccines, but the health secretary was rarely mentioned.
Ugur Sahin and Özlem Türeci, the couple who co-founded BioNTech, are leaving the Covid-19 vaccine maker to start a new, mRNA-focused firm.
Strategic angle: Gary Woodland reveals his struggle with post-traumatic stress disorder following brain surgery.
Strategic angle: Vertex reported that its drug, acquired for $4.9 billion, halved a key marker of IgA nephropathy in late-stage trials.
Strategic angle: A groundbreaking approach using CRISPR technology shows promise in treating heart failure by enhancing mitochondrial function.
Strategic angle: Researchers discover new functions of the cereblon protein that could enhance cancer drug efficacy.
Strategic angle: Wall Street's verdict on Prasad, generic semaglutide's new pricing, and other biotech news